TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q1 2025
Holdings as of Mar 31, 2025, filed May 14, 2025. Long positions only; changes compare share counts with Q4 2024.
- Positions
- 37
- −1 vs. Q4 2024
- Portfolio value
- $733.1M
- −$290.3M (−28.4%) vs. Q4 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| CGONCG Oncology, Inc. | COM | 3,670,206 | $89.9M | 12.3% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 6,964,375 | $41.7M | 5.7% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,890,816 | $41.6M | 5.7% | 00.0% | Unchanged | History |
| MLYSMineralys Therapeutics, Inc. | COM | 2,470,265 | $39.2M | 5.4% | 00.0% | Unchanged | History |
| OCULOcular Therapeutix, Inc | COM | 5,319,148 | $39.0M | 5.3% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 6,056,596 | $37.9M | 5.2% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 12,362,205 | $34.2M | 4.7% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 2,650,150 | $27.7M | 3.8% | 00.0% | Unchanged | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,501,624 | $27.2M | 3.7% | 00.0% | Unchanged | History |
| TYRATyra Biosciences, Inc. | COM | 2,898,103 | $27.0M | 3.7% | +909,000+45.7% | Added | History |
| XNCRXencor Inc | COM | 2,452,138 | $26.1M | 3.6% | 00.0% | Unchanged | History |
| IRONDisc Medicine, Inc. | COM | 465,257 | $23.1M | 3.2% | −21,700−4.5% | Reduced | History |
| TRMLTourmaline Bio, Inc. | COM | 1,477,593 | $22.5M | 3.1% | 00.0% | Unchanged | History |
| CDTXCidara Therapeutics, Inc. | COM NEW | 1,005,901 | $21.7M | 3.0% | 00.0% | Unchanged | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 5,943,812 | $21.0M | 2.9% | +1,300,000+28.0% | Added | History |
| SLNOSoleno Therapeutics Inc | COM | 275,000 | $19.6M | 2.7% | −275,000−50.0% | Reduced | History |
| EYPTEyePoint, Inc. | COM NEW | 3,572,335 | $19.4M | 2.6% | 00.0% | Unchanged | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 1,063,000 | $18.4M | 2.5% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 2,801,763 | $17.1M | 2.3% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM | 13,090,200 | $16.0M | 2.2% | −45,060−0.3% | Reduced | History |
| FULCFulcrum Therapeutics, Inc. | COM | 5,250,000 | $15.1M | 2.1% | 00.0% | Unchanged | History |
| ATXSAstria Therapeutics, Inc. | COM | 2,761,861 | $14.7M | 2.0% | 00.0% | Unchanged | History |
| TNGXTango Therapeutics, Inc. | COM | 10,736,000 | $14.7M | 2.0% | 00.0% | Unchanged | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 3,858,000 | $11.0M | 1.5% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $9.40M | 1.3% | 00.0% | Unchanged | History |
| THRDThird Harmonic Bio, Inc. | COM | 2,505,424 | $8.69M | 1.2% | 00.0% | Unchanged | History |
| SLNSilence Therapeutics plc | ADS | 3,033,560 | $8.55M | 1.2% | 00.0% | Unchanged | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 1,796,482 | $7.85M | 1.1% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM | 2,676,580 | $6.69M | 0.9% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 2,240,809 | $5.62M | 0.8% | 00.0% | Unchanged | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $5.29M | 0.7% | 00.0% | Unchanged | History |
| MBXMBX Biosciences, Inc. | COM | 650,000 | $4.80M | 0.7% | 00.0% | Unchanged | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 483,000 | $3.87M | 0.5% | 00.0% | Unchanged | History |
| KODKodiak Sciences Inc. | COM | 1,145,538 | $3.21M | 0.4% | 00.0% | Unchanged | History |
| NKTRNektar Therapeutics | COM | 4,000,000 | $2.72M | 0.4% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 316,195 | $363.6K | <0.1% | 00.0% | Unchanged | History |
| CABACabaletta Bio, Inc. | COM | 86,795 | $120.2K | <0.1% | 00.0% | Unchanged | History |
Sold out since Q4 2024 (1)
Positions held at the end of Q4 2024 that are gone from this filing.